Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) had its target price hoisted by investment analysts at JonesTrading from $50.00 to $82.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. JonesTrading's target price would suggest a potential upside of 214.97% from the stock's current price.
A number of other research firms have also recently issued reports on RAPP. UBS Group initiated coverage on Rapport Therapeutics in a report on Thursday, October 15th. They issued a "buy" rating and a $71.00 price target for the company. Wall Street Zen lowered shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Wolfe Research initiated coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set an "outperform" rating and a $50.00 target price on the stock. Citigroup reiterated an "outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday. Finally, TD Cowen reissued a "buy" rating on shares of Rapport Therapeutics in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Rapport Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $68.36.
Read Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Stock Performance
Rapport Therapeutics stock traded down $3.34 during trading hours on Wednesday, hitting $26.03. 1,311,854 shares of the stock were exchanged, compared to its average volume of 397,603. The stock has a market capitalization of $1.25 billion, a P/E ratio of -8.51 and a beta of 1.22. Rapport Therapeutics has a 12 month low of $23.75 and a 12 month high of $52.93. The business's 50-day moving average is $40.31 and its two-hundred day moving average is $39.13.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, equities analysts predict that Rapport Therapeutics will post -4.09 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Abraham Ceesay sold 28,958 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the completion of the sale, the chief executive officer directly owned 486,108 shares of the company's stock, valued at $23,338,045.08. The trade was a 5.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Cheryl Gault sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total transaction of $331,900.00. Following the completion of the transaction, the chief operating officer owned 139,914 shares in the company, valued at $4,643,745.66. This represents a 6.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 97,976 shares of company stock worth $4,420,349 in the last ninety days. Insiders own 12.48% of the company's stock.
Institutional Trading of Rapport Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth about $888,000. Wellington Management Group LLP raised its position in shares of Rapport Therapeutics by 11.2% in the 2nd quarter. Wellington Management Group LLP now owns 86,988 shares of the company's stock valued at $3,625,000 after acquiring an additional 8,757 shares during the period. Artia Global Partners LP acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $5,772,000. Bank of America Corp DE bought a new position in Rapport Therapeutics during the 2nd quarter worth approximately $3,170,000. Finally, Jupiter Topco LLC bought a new position in Rapport Therapeutics during the 2nd quarter worth approximately $574,000.
Trending Headlines about Rapport Therapeutics
Here are the key news stories impacting Rapport Therapeutics this week:
- Positive Sentiment: Rapport reported that its Phase 2 trial of RAP-219 met both the primary and secondary endpoints. At Week 3, the treatment produced a statistically significant placebo-adjusted 3.1-point improvement in the Young Mania Rating Scale and a 0.4-point improvement in the Clinical Global Impression–Bipolar severity score. Rapport Phase 2 topline results
- Positive Sentiment: The company plans to advance RAP-219 into Phase 3 bipolar-mania trials, reducing some development uncertainty and supporting the potential for a larger commercial opportunity. Rapport plans Phase III trials
- Positive Sentiment: Analysts responded favorably: BTIG raised its price target to $89 from $75, Raymond James increased its target to $86 from $75, and HC Wainwright reaffirmed a Buy rating with a $66 target. Analysts have cited a potential blockbuster opportunity, with estimated peak sales near $1 billion. Raymond James price target increase
- Neutral Sentiment: Investor reaction has been volatile, with unusually heavy trading volume following the data release as the market weighs the clinical results and the transition toward Phase 3. Rapport trading volume
- Negative Sentiment: Some coverage characterized the trial win as modest because RAP-219 fell short of the study’s original ambitions, which may explain profit-taking and the stock’s continued weakness despite positive headline results. Rapport Phase 2 analysis
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.
Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.